Seres Therapeutics, Inc. (MCRB) Dividend History

Company News

• Denodo University Challenge Now Open: Data and AI for Real-World Impact

  Denodo, a leader in data management, has announced the Denodo University Challenge, 'Data and AI for Real-World Impact', which aims to encourage students to develop innovative AI-driven solutions that have a demonstrable impact on social and economic challenges. The challenge will leverage Denodo's data management and AI tools, including the Denodo Platform and the Denodo AI SDK.

  GlobeNewswire Inc.
• Seres Therapeutics Presents Expanded SER-155 Exploratory Biomarker Data at 2025 ASCO Annual Meeting

  Seres Therapeutics presented new exploratory biomarker data from its SER-155 Phase 1b study, showing evidence of improved intestinal epithelial barrier integrity, modulation of systemic inflammatory responses, and potential to promote immune reconstitution after allogeneic hematopoietic stem cell transplant.

  GlobeNewswire Inc.
• Microbiome Disease Pipeline Insight 2025: Over 180 Drugs in Development Across 140+ Companies

  The Microbiome Disease Pipeline Report 2025 reveals 180+ drugs under development across 140+ companies, covering late-stage, mid-stage, and early-stage therapies. Major players such as MaaT Pharma, Seres Therapeutics, Biomica, and Vedanta Biosciences are advancing Phase III and II candidates targeting microbiome-related conditions.

  GlobeNewswire Inc.
• Microbiome Disease Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 140+ Companies and 180+ Therapies | DelveInsight

  The microbiome disease pipeline is a robust space with 140+ active players working to develop 180+ pipeline microbiome disease drugs. Key companies like MaaT Pharma, Qu Biologics, Biomica Ltd., and Seres Therapeutics are evaluating new microbiome disease drugs to improve the treatment landscape.

  GlobeNewswire Inc.
• Seres Therapeutics Announces Receipt of Expected $50 Million Installment Payment Related to VOWST Sale

  Seres Therapeutics announced the receipt of a $50 million installment payment related to the sale of its VOWST business to Nestlé Health Science. The company expects to fund operations into the first quarter of 2026 based on its existing cash, including this payment and a projected installment payment from Nestlé Health Science in July 2025.

  GlobeNewswire Inc.